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Abstract
Exclusive enteral nutrition (EEN) is a well-establised primary therapy in active pediatric 
Crohn’s disease (CD). EEN promotes mucosal healing, restores bone mineral density, 
and improves growth. On the contrary, treatment of active CD with corticosteroids (CS) 
has a strong negative impact on the linear growth and bone density. Therefore, EEN is 
recommended as a first-line therapy in children with active CD. EEN has been evalu-
ated in a number of clinical studies including randomized controlled trials. While meta-
analyses of adult studies suggest superiority of CS, pediatric studies have shown that 
EEN is at least as effective as CS in inducing remission. The mechanisms by which EEN 
suppresses inflammation are not yet fully elucidated. Hypotheses include improvement 
in nutritional status, decreasing of the inflammatory cascade mechanism, limiting lumi-
nal antigen exposure, improving intestinal permeability, and modification of intestinal 
microbiota.
Keywords: Crohn’s disease, exclusive enteral nutrition, partial enteral nutrition, 
children, adults
1. Introduction
Inflammatory bowel disease (IBD) is an immune-mediated condition, which includes Crohn’s 
disease (CD), ulcerative colitis (UC), and IBD-unclassified (IBD-U) [1]. Nearly 25% of patients 
are diagnosed before 16 years of age. A number of studies have shown that pediatric-onset 
IBD presents with a more difficult phenotype when compared to adult-onset IBD and may 
have the consequences of growth retardation and delayed puberty as well as the psycho-
logical consequences of disease onset at a very vulnerable time of psychosocial development 
[2–5].
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Exclusive enteral nutrition (EEN) is successful in the treatment of undernutrition. Moreover, 
EEN is able to induce remission in CD patients with active inflammation. The European 
Society of Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European 
Crohn’s Colitis Organization (ECCO) recommend EEN as a first-line therapy in children with 
active CD and emphasize the use of EEN over CS in all children with active inflammatory 
intestinal luminal disease, including colonic involvement [6].
The therapy with EEN provides all of the nutritional needs by a liquid formula either orally 
or through a nasogastric tube. EEN is usually recommended for 6–8 weeks, and after this 
period, a normal diet is gradually reintroduced. For EEN therapy, elemental, semi-elemen-
tal, or polymeric formulas may be used. Elemental formulas are based on amino acids and 
contain no whole proteins, while semi-elemental formulas do contain peptides of varying 
lengths. Polymeric formulas are based on whole proteins and are therefore more palatable 
[7]. In addition, polymeric formulas usually cost less. The choice of formula most frequently 
depends on the clinician’s experience and local availability [8].
EEN is especially recommended in CD children with stunted growth and in those presenting 
with low weight and a catabolic state. If EEN is not tolerated orally, a nasogastric tube may 
be used [6].
Nevertheless, EEN therapy remains underused in clinical practice, especially in adults in 
whom its efficacy in achieving clinical remission is considered to be less than the standard 
anti-inflammatory therapies [9].
In current review, different aspects of EEN as well as partial enteral nutrition (PEN) will be 
addressed, including their efficacy, treatment modalities, impact on mucosal healing, mecha-
nisms of anti-inflammatory effects, and the role of enteral nutrition in maintaining remission.
2. The history of exclusive enteral nutrition
The first report on successful use of enteral feeding was published in 1973 by Voitk et al. It 
demonstrated improvement in inflammatory indices and weight gain in 13 patients. Nine of 
them were planned for surgery and two of them were able to avoid it after a period of exclu-
sive elemental formula treatment [10].
In 1981, Logan et al. found a decrease in the number of gut lymphocytes and diminished 
protein loss when elemental enteral nutrition was used in patients with extensive small bowel 
CD [11].
Navarro et al. studied the efficacy of continuous elemental EEN on 17 pediatric patients 
with active CD and demonstrated that EEN was successful in inducing clinical remission. 
Additionally, therapy with EEN was proven to be safe and well tolerated [12].
Five years later, O’Morain et al. found that elemental EEN was equally successful or even 
more effective than steroids in inducing clinical remission in adults with active CD [13]. 
However, in 1995, a meta-analysis by Griffiths et al. demonstrated that therapy with EEN 
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was significantly less effective compared to CS in a mixed population of adult and pediatric 
patients with CD [14]. But in 1997, in a randomized controlled trial by Zoli et al., EEN with an 
elemental diet was again shown to be equally effective as CS in inducing remission in a cohort 
of adult patients with both mild and moderately active CD [15].
3. Elemental versus polymeric enteral feeds
In the 1990s, both elemental and polymeric enteral nutrition were used in the largest pediatric 
inflammatory centers in United Kingdom as a first line of treatment of active CD. Clinical 
studies were then conducted to compare elemental versus polymeric enteral formulas [16]. In 
a randomized controlled trial by Rigaud et al., no significant difference was found in induc-
ing clinical remission in adult CD patients between elemental and polymeric enteral formulas 
[17]. Ludvigsson et al. conducted a multicentre randomized control trial to compare the effi-
cacy of elemental and polymeric formulas in children with active CD. The efficacy in inducing 
remission was found not to be different between elemental (E028E; Nutricia) and polymeric 
formulas (Nutrison Standard; Nutricia). However, patients who were receiving polymeric 
formula had better weight gain [18].
In a meta-analysis by Griffits et al., the efficacy of EEN therapy with elemental versus nonele-
mental formulas was compared. They demonstrated that there was no significant difference 
in the efficacy between the elemental and nonelemental formulas [14].
4. The efficacy of exclusive enteral nutrition versus corticosteroids
EEN has been evaluated in a number of clinical studies including randomized controlled tri-
als (RCTs) that compared EEN with CS in adult and pediatric populations of patients with 
active CD. To date, eight meta-analyses have been published on the efficacy of EEN versus 
CS. Among these meta-analyses, three of them were performed exclusively on the pediat-
ric population, whereas others included adult patients as well. While meta-analyses of adult 
studies have suggested better efficacy of CS, pediatric studies have shown that EEN is at least 
as effective as CS in inducing remission and is superior to CS in improving nutritional status 
and growth recovery without adverse side effects [19].
4.1. Efficacy of EEN versus CS in adult and mixed population of CD patients
In the first meta-analysis by Fernandez-Banares et al., the therapy with EEN was significantly 
less effective compared to CS. The meta-analysis included nine trials with mostly adult CD pop-
ulations. The overall remission rate was 57.7% for EEN and 79.4% for CS [20]. A meta-analysis 
by Messori et al. included studies exclusively on the adult CD population which compared the 
effectiveness of EEN versus CS. The patient-specific end-point of the meta-analysis was occur-
rence of treatment failure. CS were more effective than EEN for inducing remission in adult 
active CD. In fact, the relative risk of treatment failure (RTF) was significantly lower in the steroid 
Exclusive and Partial Enteral Nutrition in Crohn’s Disease
http://dx.doi.org/10.5772/intechopen.72734
71
group than in the EEN group. They concluded that the data examined in this meta-analysis do 
not support the use of EEN as primary treatment for acute exacerbations of CD in adults [21]. 
In 1995, Griffiths et al. included eight RCTs (mixed adult and pediatric CD of 413 patients) com-
paring EEN with CS. Odds ratios (OR) for likelihood of clinical response were calculated. They 
found that EEN was inferior to CS (OR 0.35; 95% CI 0.23–0.53) [14]. A similar meta-analysis was 
performed in 2001 by the same team of authors from Toronto. In accordance with the stricter 
inclusion criteria, only four RCTs were included (130 patients treated with EEN and 123 treated 
with CS). The meta-analysis yielded a pooled OR for remission of 0.30 favoring CS therapy (95% 
CI 0.17–0.52) [22]. This meta-analysis was updated in 2007 and included six clinical trials with 
192 patients treated with EEN and 160 treated with CS. The pooled OR for remission, after com-
bining all type of enteral diets and comparing them with CS therapy, was 0.33 favoring steroid 
therapy (95% CI: 0.21–0.53) [23].
4.2. Efficacy of EEN versus CS in pediatric CD population
The first meta-analysis on pediatric population was published in 2000 by Heuschkel et al. The 
meta-analysis included five RCTs and was composed of 147 pediatric patients with active CD, 
and it demonstrated that EEN was equally effective as CS in inducing remission (relative risk 
(RR) = 0.95; 95% CI: 0.67–1.34). EEN was, however, superior in improving growth and pubertal 
development. Additionally, EEN seemed to be without the side effects. According to the results 
of this meta-analysis, EEN was then recommended as a first-line therapy in children with active 
CD [24]. The same results were demonstrated 7 years later in a meta-analysis by Dziechciarz 
et al. Only four RCTs (144 pediatric CD patients) met the inclusion criteria. No significant dif-
ference in remission rates between the patients receiving EEN and CS was found [25].
In the most recent published meta-analysis by Swaminath et al., eight clinical studies (451 
pediatric CD patients) were included based on the inclusion criteria and availability of data 
that could be abstracted into meta-analysis. The efficacy in inducing remission was not dif-
ferent between EEN and CS (OR = 1.26; 95% CI 0.77–2.05). The authors also compared the 
efficacy between EEN and CS treatment in newly diagnosed CD patients (OR = 1.61; 95% CI 
0.87–2.98) with relapsed patients (OR = 0.76; 95% CI 0.29–1.98) [26].
5. Recommendations on exclusive enteral nutrition in adult patients 
with Crohn’s disease
To date, according to the results of meta-analyses on the adult CD population, EEN appears to 
be less effective than CS. Therefore, therapy with EEN is used as a first-line treatment in active 
CD only when therapy with CS is contraindicated [27].
In the current ECCO consensus guidelines for medical management of adult CD, therapy with 
enteral nutrition is regarded as a complementary treatment to improve nutrition and not as a 
primary therapy. It is still considered appropriate to use EEN in patients who decline all other 
drug therapies [28]. Further studies on EEN use as a primary therapy to induce remission 
in adult CD patients are needed to clarify the efficacy of EEN. The reasons for the difference 
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in the efficacy of EEN between the pediatric and adult CD population have still not been 
elucidated. In adult IBD patients, who have a longer disease course and more frequent com-
plications, EEN may be less effective. EEN may not be so strictly adhered to in adult patients, 
when compared to children, who are supervised by their parents. Furthermore, children and 
especially adolescents are generally more motivated to achieve success through this therapy. 
Most of them refuse CS treatment due to the unpleasant side effects related to appearance 
such as facies lunata, acne vulgaris, and increased hairiness.
6. Exclusive enteral nutrition and mucosal healing
Mucosal healing is an important therapeutic endpoint that, when achieved early, is associated 
with fewer hospitalizations, reduced surgical resections, lower risk of fistulizing disease, and 
less use of biologic drugs [29–32]. It is well established that treatment with EEN is capable of 
achieving mucosal healing in CD. On the contrary, CS have poor ability to induce mucosal 
healing. A study made in 1990, on the effects of prednisolone on mucosal healing in patients 
with active CD, found that 27% of patients still had minor lesions and only 12% achieved com-
plete mucosal healing after 4–7 weeks of CS therapy [33]. Similarly, none out of eight patients 
with CD, treated with prednisolone for postoperative recurrence, showed mucosal healing 
after 6–9 weeks, based on the overall endoscopic assessment of the mucosa rather than a 
detailed endoscopic score [34]. These findings suggest that CS have little or no positive effects 
on induction of mucosal healing in CD. In a RCT in children with active CD, Borrelli et al. 
compared not only the efficacy of EEN versus CS in inducing clinical remission but also in 
achieving mucosal healing. The therapy with EEN was superior in achieving mucosal healing 
compared to CS. Mucosal healing was found in 14 of 19 CD patients (74%) in the EEN group 
and in 6 of 18 patients in the CS group (33%, p < 0.05) [35]. In a retrospective study by Berni 
Canani et al., 65% of pediatric CD patients on EEN therapy and 40% on CS (p < 0.05) achieved 
improvement in mucosal inflammation. Seven patients on EEN and none on CS were found 
to have complete mucosal healing (p < 0.005) at the end of treatment. In addition, the duration 
of clinical remission was longer in the EEN group when compared with the CS group [36]. 
Recently, Grover et al. had used the Simple Endoscopic Score for CD (SES-CD) to define endo-
scopic mucosal lesions in 26 children with active CD receiving EEN for 8 weeks. At the end of 
the EEN therapy, 42% of patients had complete mucosal healing (SES-CD = 0) and the other 
58% had complete or near-complete mucosal healing (SES-CD < 3) [37]. Mucosal healing after 
EEN therapy was also demonstrated in the adult population of active CD patients. In a study 
by Yamamoto et al., a 4-week therapy with EEN has shown a complete endoscopic remission 
rate of 44% in the terminal ileum and 39% in the colon [38]. In a recent pediatric meta-analysis 
by Swaminath et al., two pediatric studies provided data on mucosal healing at the end of 
induction therapy with EEN versus CS [35, 36]. The occurrence of mucosal healing was sig-
nificantly more likely in the group of CD children, who were receiving EEN, compared to 
those receiving CS (OR = 4.5; 95% CI 1.64–12.32) [26]. Furthermore, Rubio et al. compared 
fractionated oral versus continuous enteral feeding in terms of clinical and mucosal healing 
and have demonstrated similar rates of mucosal healing in patients receiving ether fraction-
ated or continuous enteral feeding [39].
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7. Disease location and efficacy of exclusive enteral nutrition
In the early 2000s, EEN was especially used in CD patients with small bowel disease. That 
was in accordance with the results of a clinical trial by Afzal et al. which have shown that 
EEN was less effective in CD patients with colonic disease in comparison with those who 
had only small bowel involvement or small and large bowel disease [40]. However, recent 
studies and meta-analyses have not confirmed this negative association [23, 25]. Buchanan 
et al. found no significant differences in remission rates in terms of disease location [41]. 
Similar findings were reported in a study by Rubio et al. where the site of disease activity 
had no impact on response to nutritional therapy [39]. The same results were demonstrated 
in a study by Gupta et al. where the location of the inflammation in CD did not affect the 
efficacy of EEN [42].
8. The long-term efficacy of exclusive enteral nutrition
The long-term efficacy of the induction therapy with EEN is not yet well established. Studies 
comparing the long-term outcomes of EEN versus CS treatment are limited. In a retrospec-
tive study by Lambert et al., a lower 1-year (61 versus 77%) and 2-year relapse rate (61 versus 
89%) was demonstrated in CD children who were treated with EEN in comparison with those 
receiving CS [43]. Grover et al. have shown that induction therapy with EEN was superior to 
CS in reducing growth failure, CS dependency, and loss of response to infliximab over the 
first 2 years [44]. In a retrospective German study, most of the pediatric patients with active 
CD, treated with EEN, relapsed during the first year. Fortunately, 66% of them responded to a 
second course of EEN with remission [45]. In a recent study by Connors et al., both short- and 
long-term outcomes of EEN and CS induction therapy were examined. Out of 127 patients 
reviewed, a total of 111 propensity score-matched CD patients receiving EEN (n = 76) or 
CS (n = 35) were analyzed. Their data showed that clinical remission after EEN was supe-
rior to that after CS treatment, with 86.6 versus 58.1% of patients reaching remission within 
4–12 weeks of starting treatment. This study supports a more optimistic view toward EEN 
as an approach to CS avoidance: over 40% of EEN-treated patients in their cohort remained 
steroid naive for at least 4 years. In addition, patients treated with EEN exhibited significantly 
greater improvement in height z-scores than patients treated with CS, at 1-year follow-up. 
The therapy with EEN over CS for induction of remission was associated with avoidance of 
CS over a 6-year follow-up period. This study showed that long-term steroid avoidance via 
EEN therapy is feasible without an increased need for escalation to anti-tumor necrosis factor 
alpha (anti-TNF-α). Most of the patients in the EEN-treated group who remained steroid-
naive for 2 and 4 years had also not been exposed to anti-TNF-α, indicating that early anti-
TNF-α use could account for only a minor portion of steroid avoidance in this group. They 
concluded that EEN induction therapy is more effective in achieving early remission and is 
associated with long-term steroid avoidance without increased use of biologics or need for 
surgery [46].
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9. Current practice
Despite the reported benefits, EEN is not universally used in pediatric centers. Wide differ-
ences have been noted in the use of EEN between pediatric gastroenterologists in Europe and 
North America [47, 48]. A questionnaire-based study by Whitten et al. has shown wide varia-
tions in EEN protocols used in different areas of the world. Thirty-five centers were included 
in the study. The most centers recommend a 6–8 week therapy with polymeric formula and 
the gradual introduction of food quantity over 4–6 weeks [49].
10. The role of exclusive enteral nutrition in improvement of 
nutritional status and linear growth
Patients with IBD and especially children and adolescents often present with symptoms of 
undernutrition [50]. Both inflammation and undernutrition contribute to decreased height 
velocity [5]. Linear growth patterns correlate with disease activity, and there is strong patho-
physiological evidence that inflammation interferes with the growth hormone axis [51, 52]. 
EEN decreases proinflammatory cytokines, including IL-6 and TNF-α, after which an increase 
in growth hormones (IGF-1 and IGFBP-3) is observed within 2 weeks of treatment [53]. It is 
not only that EEN decreases inflammation, it improves malnutrition and other specific nutri-
tional deficiencies as well. Nutritional supplementation plays an important role in linear growth 
improvement. Importantly, EEN may also influence growth recovery in pediatric CD patients 
by limiting chronic corticosteroid exposure, which is a significant contributing factor toward 
growth failure [46, 54].
11. The role of preoperative exclusive enteral nutrition
To date, few experiences have been reported on the role of preoperative EEN in diminishing 
postoperative complications after bowel resections or other surgical interventions in patients 
with IBD. Li et al. investigated the influence of preoperative 3-month EEN on the incidence of 
postoperative intra-abdominal septic complications in CD patients with enterocutaneous fistu-
las. A retrospective study on 123 CD patients suffering from enterocutaneous fistulas was per-
formed. The patients were divided into an EEN or a non-EEN group. A significantly lower rate of 
postoperative intra-abdominal septic complications was demonstrated in the EEN group versus 
the non-EEN group (3.6 versus 17.6%, p < 0.05). The results of this study have shown that pre-
operative EEN is an important factor for reduced risk of postoperative intra-abdominal septic 
complications [55]. The authors from the same IBD centre conducted another study to evaluate 
the impact of EEN on the perioperative outcome in CD patients following immunosuppressive 
therapy. There was a significant difference observed in the incidence of postoperative compli-
cations between the groups of CD patients who received and those who did not receive EEN 
(p < 0.05). In addition, the use of EEN decreased the need for urgent surgery and reoperation [56].
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12. Mechanisms of action of exclusive enteral nutrition
Therapy with EEN substantially attenuates intestinal inflammation in CD patients. However, 
the mechanisms by which EEN suppresses inflammation are not yet fully understood. 
Hypotheses include improvement in nutritional intake and nutritional status, decreasing of 
the inflammatory cascade mechanism, limiting luminal antigen exposure, improving intes-
tinal permeability, and modification of the intestinal microbiota [57]. Significant progress 
has been made in understanding mechanisms of how EEN suppresses inflammation. Basic 
research has demonstrated that EEN has direct anti-inflammatory properties, can correct 
localization of tight junction proteins and has other important impacts on intestinal perme-
ability, alters micro RNAs expression, and profoundly affects the intestinal microbiota [58].
12.1. Anti-inflammatory effect of EEN
It is clear that EEN suppresses intestinal inflammation. In 1981, Logan et al. found a decrease in 
the number of gut lymphocytes and diminished protein loss when elemental enteral nutrition 
was used in patients with extensive small bowel CD [11]. In 1995, Breese et al. demonstrated 
that therapy with EEN reduced the number of lymphokine-secreting cells in the gut mucosa 
in CD [59]. Three years later, Beattie et al. reported on different mechanisms of action of EEN 
in CD. EEN was shown to be able to reduce the number of cytokine-producing cells in the 
inflamed mucosa of CD patients [16]. In a study by Fell et al., a decline in ileal and colonic inter-
leukin-1beta mRNA was observed after 8 weeks of oral polymeric diet. In addition, a decrease 
of interferon gamma mRNA with a rise of transforming growth factor beta1 mRNA was dem-
onstrated in the ileum and a fall of interleukin-8 mRNA in the colon [60]. Yamamoto et al. suc-
cessfully managed acute duodenal CD with a low-speed elemental diet infusion via nasogastric 
tube in a 28-year-old female and also demonstrated that the duodenal mucosal cytokine levels 
remarkably decreased compared with those before the treatment [38]. Recently, Nahidi et al. 
cocultured heat tolerance (HT)-29 colonic epithelial cells with TNF-α in the presence or absence 
of polymeric formula, as used for EEN. Microarray analysis showed that polymeric formula 
modulated the expression of genes involved in the nuclear factor kB pathway with consequent 
downregulation of IL-6 and IL-8 proteins [61]. Alhagamhmad et al. wanted to find out whether 
the specific components in the polymeric formula drive the demonstrated attenuation of the 
nuclear factor kB cascade. They used tumor necrosis factor-α-exposed HT-29 colonic epithelial 
cells to investigate the immunosuppressive activity of the glutamine, arginine, vitamin D3, and 
α-linolenic acid (ALA), present in polymeric formula, along with curcumin. They found out 
that glutamine, arginine, and vitamin D3, but not ALA, significantly attenuated IL-8 produc-
tion. Glutamine and arginine led to a phosphorylation blockade of the signaling components 
in NF-κB and P38 pathways, reduction in kinase activity, and enhancement in NO produc-
tion. They concluded that glutamine, arginine, and vitamin D3 can suppress inflammation at 
concentrations equivalent to those used in polymeric formula. According to these findings, 
glutamine and arginine-fortified polymeric formulas might be a promising option to enhance 
the effectiveness of EEN therapy in CD treatment [57]. There is accumulating evidence that 
microRNAs play an important role in CD pathogenic processes, including regulation of pro 
and anti-inflammatory pathways. Guo et al. performed a microarray analysis in 25 adult CD 
patients and 10 healthy individuals treated with EEN. The microarray analysis showed that the 
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mucosal micro RNAs expression profile is significantly altered after EEN therapy compared 
with the one in inflamed mucosa before EEN treatment [62]. The Australian investigators dem-
onstrated that polymeric formula had a direct anti-inflammatory effect on colonic enterocytes. 
Polymeric formula was able to reduce interleukin (IL)-8 response to proinflammatory stimuli 
when it was added to the culture medium. The authors concluded that polymeric formula may 
modulate gut inflammation by directly reducing the inflammatory response of the intestinal 
epithelium [63]. Recently, the same team of investigators found that the incubation of human 
cells (Caco-2 human adenocarcinoma cell line) with a polymeric formula resulted in a dose-
dependent increase in the expression of intestinal alkaline phosphatase, which is a recognized 
marker of enterocyte differentiation. Intestinal alkaline phosphatase is implicated in the innate 
gut immune response to enteric pathogens. This finding suggests that cell surface-associated 
intestinal alkaline phosphatase may be an aspect of the gut’s innate immune response to patho-
genic bacteria that is strengthened by polymeric formula [64].
12.2. Reduction in dietary antigen exposure
In the first years, only elemental formulas were used for the treatment of active CD. It was 
believed that the effect of EEN was based on exclusion of the dietary antigens which might 
have a role in inducing and promoting the inflammatory cascade. However, later research has 
shown that whole protein polymeric formulas were also as effective in inducing remission in 
patients with active CD [14, 18, 22, 65, 66].
12.3. The role of fats in EN formulas
The influence of the lipid source within the enteral feeds has been examined, but how the 
lipids composition of enteral nutrition affects its efficacy remains to be elucidated. In a meta-
analysis by Zahos et al., the efficacy between the elemental formulas with low fat content 
(< 20 g/1000 kcal) versus high fat content (> 20 g/1000 kcal) was compared. This meta-analysis 
did not demonstrate a significant difference in efficacy of the two types of elemental formulas 
[23]. In the last decades, the impact of the use of fatty acids as potential immune-modulating 
agents in an inflammatory condition such as CD has been studied [67]. Recently, in a double-
blind RCT by Grogan et al., a modest effect on the blood fatty acid composition was seen 
with both nutritional interventions (with Alicalm and Emsogen). After an intervention with a 
6-week therapy with Alicalm, an increase of eicosapentaenoic acid (EPA) and alpha linolenic 
acid (ALA) was demonstrated with an inverse decrease in arachidonic acid (AA). Arachidonic 
acid is an important precursor to eicosanoids, which are second messengers in numerous sig-
nal transduction processes and have proinflammatory properties. The authors of this study 
concluded that there may be an advantage of using enteral formula that contains increased 
levels of ALA, as it is a precursor of anti-inflammatory eicosanoids [68].
12.4. Glutamin and arginine in EN formulas
Glutamine and arginine are conditionally essential amino acids with immunomodulatory 
properties. Glutamine may be essential in patients with catabolic conditions where the inter-
vention with glutamine-supplements is able to prevent the deterioration of gut permeability 
and development of intestinal mucosal atrophy [69–71]. Akobeng et al. conducted a RCT, 
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which included 18 pediatric patients with active CD, who were randomly assigned to receive 
a 4-week course of either: standard polymeric formula with low glutamine content (4% of 
amino acid composition) or a glutamine-enriched polymeric diet (42% of amino acid compo-
sition). They found no significant difference between these two types of formula in terms of 
clinical efficacy [72]. In a recent meta-analysis of the same authors, only two small RCTs (total 
42 patients) met the inclusion criteria. The first study is the aforementioned pediatric study 
by Akobeng et al. [72]. In the second study, 24 adult CD patients with acute exacerbation of 
IBD were treated either with glutamine-supplemented or non-supplemented total parenteral 
nutrition. In both included studies, no statistically significant changes in intestinal permeabil-
ity were found between patients, who received glutamine supplementation and those who 
did not [73]. Further randomized controlled clinical studies on the efficacy and safety of glu-
tamin supplementation in patients with active CD are needed.
12.5. The impact of EEN on gut microbiota
While all the pathogenetic mechanisms of action of EEN have not yet been elucidated, EEN is 
known to cause profound changes in the gut microbiome. Understanding how EEN modifies 
the gut microbiome to induce remission could provide insight into CD etiopathogenesis and 
consequently guide the development of microbiome-targeted interventions [74]. In 2005, Lionetti 
et al. assessed clinical remission and the fecal microbiota in nine children with active CD treated 
with EEN. Clinical remission was observed in eight of nine children. In all these patients, sig-
nificant modification of the fecal microbiota was found after EEN therapy. In contrast, control 
healthy children showed a host-specific and stable microbiota over time [75]. Similarly, Leach 
et al. demonstrated a significantly different composition of intestinal microbiota in patients with 
CD treated with EEN in comparison with the microbiota of control subjects. The effect of mod-
ificated microbiota remained present for 4 months after EEN [76]. EEN was shown to promote 
protective species and increase the production of butyrate [77]. Surprisingly, in a Scottish study 
which included 15 pediatric patients with CD before and after remission with EEN and 21 control 
subjects, the therapy with EEN was associated with a decrease in diversity of microbiota and not 
vice versa as was expected. A decrease in specific ‘protective’ species including F. prausnitzii was 
found as well as a fall in butyrate in fecal samples. These results have challenged the current per-
ception of a protective role of F. prausnitzii in CD [78]. Quince et al. have analyzed microbiota in 
23 CD children and in 21 healthy controls before, during, and after EEN treatment. They demon-
strated lower microbial diversity in CD patients compared with controls before EEN. During the 
therapy with EEN, the microbial diversity in CD children further decreased and the structure of 
microbiota became even more dissimilar in comparison with the healthy controls [79]. In another 
small study, similar results were shown. Fecal microbiota of five children with CD, before, dur-
ing, and after EEN treatment was analyzed and compared with five healthy controls. It showed 
a dramatic decrease in the number of operational taxonomic units (OTUs) after therapy with 
EEN. Inversely, recurrence of inflammation corresponded with an increase in OTUs [80]. In an 
extension study by Lee et al., fecal samples from patients (n = 86) treated with either PEN, EEN, 
or anti-TNF-α were analyzed using shotgun metagenomics analysis at four points of time during 
treatment and compared with healthy controls. After 1 week of treatment, the microbiota com-
position among the EEN-treated group drifted significantly farther from centroid of the healthy 
controls compared to anti-TNF-α treated patients who moved closer to the centroid. However, 
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at the end of the study, responders (those with clinical remission and reduction in fecal calpro-
tectin) were closer to the centroid of the healthy controls than nonresponders, regardless of treat-
ment, suggesting that at treatment initiation, the treatment modality is the major determinant 
affecting gut microbiota, whereas later on, the resolution of inflammation becomes the dominant 
factor. Still, the resolution of dysbiosis was not complete even among responders at 8 weeks [81].
12.6. Exclusion of specific dietary components
During the 6- to 8-week therapy with EEN, the patients with active CD should not eat any 
food, and their 100% daily caloric requirements are covered by liquid formula. Therefore, 
the therapy with EEN automatically involves exclusion of many common dietary compo-
nents which might have a deleterious effect on the intestinal mucosa. The avoidance of these 
potentially harmful dietary components might present another potential anti-inflammatory 
mechanism of EEN [82].
13. Partial enteral nutrition for maintaining remission in Crohn’s 
disease
There are some studies suggesting that nutritional supplementation with liquid formulas may 
prolong remission in patients with quiescent CD [83–85]. However, the efficacy of partial enteral 
nutrition (PEN) for maintaining remission in inactive CD has not yet been fully evaluated. On the 
contrary, the use of immunomodulators and biological medications for maintaining remission 
in CD is well established. The adverse events of these medications, such as the increased risk of 
infection and malignancy, have always been concerning [86, 87]. Therefore, we should aim for a 
safer maintenance regimen, especially in children. Maintenance enteral nutrition (MEN) could be 
an attractive option for maintaining remission of inactive CD, as it will eliminate serious adverse 
events associated with the use of immunosuppressive medications and biologics. In 1987, Jones 
et al. reported their experience with 77 (16–65 years) CD patients in clinical remission who tried 
to maintain remission by personalized food exclusion diets along with a supplementary ele-
mental diet. Twenty six of 77 (33.7%) patients remained in remission for 2 years and 18 (23.4%) 
patients for at least 3 years [88]. In a study by Wilschanski et al., pediatric patients with active 
CD who were successfully treated with EEN were assessed retrospectively according to whether 
they continued supplementary enteral nutrition or not. Time to relapse and linear growth were 
compared between the two cohorts. Patients who continued nasogastric supplementary feeding 
(n = 28) after reintroduction of their otherwise normal diet remained in remission longer than 
those who discontinued nocturnal supplementation (n = 19) (p < 0.02). Furthermore, continued 
use of nasogastric supplements before completion of puberty was associated with improved 
linear growth [85]. In 2000, Verma et al. studied a series of 39 consecutive patients with CD in 
clinical remission over 12 months. Patients in group 1 (n = 21) received oral nutritional supple-
mentation along with their normal diet and patients in group 2 (n = 18) had a normal unre-
stricted diet without the nutritional supplementation. Forty-eight percent of patients in group 1 
remained in remission for 12 months compared to the 22% of patients in group 2 (p < 0.0003) [89]. 
In 2007, Akonbeng et al. conducted a systematic review on the efficacy of enteral nutrition for 
maintenance of remission in CD. Only two studies were included based on the inclusion criteria 
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[90]. In the first study, a significant lower relapse rate was found in CD patients who received 
half of their daily nutritional needs from an elemental formula and the remaining half by normal 
diet compared to patients who only received a normal diet [90]. In the second study, the com-
parison between elemental and polymeric formulas (providing between 35 and 50% of patients’ 
caloric intake in addition to normal diet) was assessed in terms of maintenance of remission. 
Both type of formulas were equally effective in maintaining remission and allowing withdrawal 
of steroid therapy [91, 92]. Recently, Nakahigashi et al. have reviewed the efficacy of EN for the 
maintenance of remission in patients with quiescent CD. Seven prospective cohort studies were 
included and three of them were RCTs. In all studies, patients used EN as a supplement or as a 
nocturnal tube feeding in addition to their normal food. The maintained clinical remission rate at 
1 year was significantly higher in patients treated with EN in four of the six studies [93]. Although 
some studies suggest that PEN may be helpful for the maintenance of remission in the pediatric 
population [84, 85], data on the long-term usage of PEN for remission maintenance in pediatric 
CD patients are still lacking. A recent retrospective study by Schulman et al. investigated the effi-
cacy of PEN treatment in the maintenance of remission in the pediatric CD population. In their 
centre, this approach has been in practice for the last several years. They assessed 42 pediatric 
CD patients who entered clinical remission on 4–12 weeks of EEN and were maintained on PEN 
as a supplementary diet (50% of total calories obtained as polymeric formula). The control group 
consisted of patients who refused PEN. They found that the decrease in the disease activity was 
greater in the PEN group than in the control group, as was the total increase in body mass index 
between the time of diagnosis and 8 months after. Laboratory parameters, such as albumin and 
CRP, also showed better improvement in the PEN group than in the control group. Although 
PEN was able to maintain short remission in patients initially treated with EEN, most of the 
patients required concomitant medication at some point after PEN initiation. They conclude that 
PEN treatment was partially effective in maintaining remission in patients who were initially 
treated with EEN. To better assess the efficacy of PEN for maintaining remission in children 
with CD, further prospective studies are required. Recently, El-Matary et al. have published a 
systematic review on the efficacy of MEN in adult and pediatric patients with CD. Twelve studies 
(1169 patients, including 95 children) fulfilled the inclusion criteria. As the included studies were 
significantly heterogeneous, a meta-analysis was not performed. Eleven studies showed that EN 
was either better than or as effective as its comparator in maintaining remission in patients with 
inactive CD. Only one adult RCT (n = 51), with low risk of bias, compared EN with a regular diet 
and found a relapse rate of 34% in the EN group versus 64% in the control group (p < 0.01) after 
a mean follow-up of 11.9 months. The authors concluded that EN is more effective than a regular 
diet and as effective as some medications in maintaining remission for patients with inactive 
CD. Large, properly designed RCTs of sufficient duration are, however, still required to confirm 
this outcome regarding EN versus individual medications [94].
14. Partial enteral nutrition in the treatment of active Crohn’s disease
In 2006, Jones et al. have published the first RCT on partial enteral nutrition (PEN). Fifty children 
with active CD (PCDAI >20) were randomly assigned in PEN or EEN group. Children in PEN 
group had obtained 50% of their caloric requirements from elemental formula and 50% from 
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unrestricted diet, while children in EEN had received 100% of their energy requirements from 
elemental formula for 6 weeks. This study showed that the conventional treatment with EEN 
was associated with a significantly higher remission rate in comparison with PEN (42 versus 
15%) [95]. The next study on the efficacy of PEN was conducted at The Children’s Hospital of 
Philadelphia (CHOP). The authors retrospectively studied the efficacy of their CHOP protocol 
of PEN, which allowed patients to consume 10–20% of their daily caloric needs from a normal 
diet and 80–90% from enteral nutrition. In this study, a remission rate of 65% and response rate 
of 87% were demonstrated, which is comparable with the remission rate of EEN from literature. 
The authors concluded that the use of the CHOP protocol may increase compliance in the popu-
lation of pediatric CD patients by improving quality of life [42]. Recently, Sigall-Boneh et al. 
treated 47 patients (34 children and 13 young adults) with early mild-to-moderate luminal CD 
with PEN. Their approach allowed patients to consume 50% of dietary calories from a polymeric 
formula and remaining calories from a special Crohn’s disease exclusion diet (CDED). In the 
study, a clinical response and remission were achieved in 78.7 and 70.2% patients, respectively. 
Surprisingly, in six of seven patients who refused PEN and used only the specific exclusion diet 
for CD, clinical remission was observed. This study has shown for the first time that a combi-
nation of PEN with the exclusion diet was successful and led to high remission rates in early 
mild-to-moderate luminal CD, in children and young adults [96]. Furthermore, the findings of 
this study suggest that specific dietary products may play a role in the promotion of intestinal 
mucosal inflammation. The authors of this study hypothesize that the major mechanism leading 
to response to EEN used in children with active CD is exclusion of specific dietary factors which 
may have negative impact on the innate immune mechanisms of intestinal mucosa such as the 
mucous layer, intestinal permeability, or colonization and adherence with adherent-invasive 
E. coli (AIEC). They suggest that specific dietary components such as additives may impair the 
barrier function of the intestinal epithelium and allow adherence and invasion of nonpathogenic 
bacteria or bacterial antigens. Adherence of bacteria to the intestinal epithelium, penetration, 
and replication within epithelial cells, dendritic cells, and macrophages leads to continuous trig-
gering of the adaptive immune system, resulting in inflammation [97]. According to the results 
of recent epidemiological and animal model studies, they developed CDED based on exclu-
sion of dietary components hypothesized to affect the microbiome or intestinal permeability or 
other elements of innate immune system involved in CD pathogenesis [82, 97]. CDED is a struc-
tured diet that excludes animal fats, milk and dairy, gluten, and all processed and canned foods, 
which contain additives (especially emulsifiers and maltodextrin) [96]. Although the authors 
from CHOP and Israel did show that PEN may be effective in inducing the remission in active 
CD, this approach of treatment is not recommended according to the ESPGHAN/ECCO guide-
lines on the treatment of active CD in pediatric population [6]. Further studies on the efficacy of 
PEN are warranted to elucidate the efficacy of this treatment approach.
15. Conclusion
EEN is recommended as a first-line therapy for remission induction in pediatric luminal 
Crohn’s disease. Despite the inconsistent evidence regarding long-term efficacy, EEN has 
an established advantage over corticosteroids with comparable clinical efficacy but superior 
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mucosal healing effect as well as better safety profile. The exact mechanism by which EEN 
exerts its beneficial impact is still not established, particularly, whether exclusion of specific 
potentially harmful dietary components plays an important role. Nevertheless, accumulating 
evidence suggest a direct anti-inflammatory effect and an effect on the intestinal microbiota. 
The relationships between these effects and the specific triggers for the observed changes are 
yet to be elucidated.
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